Immatics Shares Surge Over 8% in Pre-Market Trading Following $35 Million Strategic Investment from Bristol Myers Squibb

Biopharmaceutical company Immatics (IMTX.US) stated,Bristol-Myers Squibb(BMY.US) has made a $35 million equity investment in Immatics. Following the news, as of press time, Immatics' pre-market stock price surged by 8.59%. Bristol-Myers Squibb will subscribe to approximately 2.42 million shares at $14.46 per share. Additionally, Bristol-Myers Squibb has the right to appoint a member to Immatics' Scientific Advisory Board.

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies.

Dr. Harpdreet Singh, CEO and co-founder of Immatics, stated: "This investment further demonstrates our close partnership and the advantages of our differentiated platform technology based on TCR cell therapies and products. We are committed to providing innovative treatment options for patients in their fight against cancer and look forward to sharing more clinical results in the second half of the year."

Editor: Guo Mingyu